Esocaid-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a dopamine D2 receptor antagonist, exerts prokinetic effects by enhancing gastrointestinal motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), selectively inhibits the H+/K+ ATPase enzyme system in gastric parietal cells, leading to a significant reduction in gastric acid secretion. The synergistic action of these two agents provides effective relief from acid-related symptoms and promotes mucosal healing. Esocaid-DSR Capsule is indicated for patients with erosive esophagitis, non-erosive reflux disease, and functional dyspepsia where acid suppression combined with improved gastric motility is desired. It should be administered as prescribed by a healthcare professional, typically before meals to optimize therapeutic outcomes. Caution is advised in patients with hepatic impairment, cardiac conditions, or those on medications known to interact with domperidone or esomeprazole. Adverse effects may include headache, dry mouth, abdominal discomfort, or rare extrapyramidal symptoms. Regular monitoring and adherence to prescribed dosage enhance safety and efficacy.